Tempest Therapeutics has secured a special license to use Senlang's technology for developing new treatments worldwide, except in China.

Nov 12, 2026, 4:44 PM ETDealRead the original at SEC EDGAR

Good for TPST

The license adds another treatment platform and candidates for cancer and autoimmune disease, and early responses support more study. The findings are still preliminary, and the license carries financial duties and development requirements.

TPST · Tempest Therapeutics, Inc.

AI read · Good for TPST

The AI's read

It gives Tempest another way to develop immune-cell treatments for cancer and autoimmune disease. Early patient findings support further study, but more follow-up is needed to understand the benefits and safety. The license also comes with financial duties and development requirements.

Get alerts for TPST

Follow Tempest Therapeutics, Inc. (TPST) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TPST

Free on the App Store and Google Play, or on the web.